Endeavor Raises $62M for New Trials for Taladegib IPF Therapy

Endeavor Raises $62M for New Trials for Taladegib IPF Therapy

282415

Endeavor Raises $62M for New Trials for Taladegib IPF Therapy

Endeavor BioMedicines has raised $62 million in series A funding to support the launch of two Phase 2 trials evaluating taladegib (ENV-101), its investigational candidate for the treatment of idiopathic pulmonary fibrosis (IPF), the company announced in a press release. The therapy is designed to target the underlying causes of the respiratory system disease. Indeed, the two studies aim to explore taladegib’s ability to slow, or even reverse, disease progression in people with IPF. In the…

You must be logged in to read/download the full post.